{
    "organizations": [],
    "uuid": "2ee3e9a7430b76a5ba884bea66b327860059f5cc",
    "author": "",
    "url": "https://www.reuters.com/article/brief-fda-confirms-date-to-providing-reg/brief-fda-confirms-date-to-providing-regulatory-guidance-for-aequus-anti-nausea-patch-idUSFWN1QP0IL",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Confirms Date To Providing Regulatory Guidance For Aequus’ Anti-Nausea Patch",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7, 2018 / 1:50 PM / Updated 12 minutes ago BRIEF-FDA Confirms Date To Providing Regulatory Guidance For Aequus’ Anti-Nausea Patch Reuters Staff March 7 (Reuters) - Aequus Pharmaceuticals Inc: * FDA CONFIRMS DATE TO PROVIDING REGULATORY GUIDANCE FOR AEQUUS’ ANTI-NAUSEA PATCH * AEQUUS PHARMACEUTICALS - FDA WILL PROVIDE FEEDBACK TO CO’S PRE-INVESTIGATIONAL NEW DRUG SUBMISSION BY APRIL END, 2018 FOR AQS1303​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-07T15:47:00.000+02:00",
    "crawled": "2018-03-07T16:12:43.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "confirms",
        "date",
        "providing",
        "regulatory",
        "guidance",
        "aequus",
        "patch",
        "reuters",
        "staff",
        "march",
        "reuters",
        "aequus",
        "pharmaceutical",
        "inc",
        "fda",
        "confirms",
        "date",
        "providing",
        "regulatory",
        "guidance",
        "aequus",
        "patch",
        "aequus",
        "pharmaceutical",
        "fda",
        "provide",
        "feedback",
        "co",
        "new",
        "drug",
        "submission",
        "april",
        "end",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}